APUS logo

APIMEDS PHARMACEUTICALS US I

APUSNYSE AMERICAN
🏆 #5064 by market capUS Equity
$4.85▼ $1.16 (−23.98%)
Market closed · at close
🔔
Track APUS
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 24.0%
7d▲ 113.7%
14d▲ 165.0%
30d▲ 27.3%
ytd▼ 73.6%
1y▼ 73.0%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$4.82 – $4.91
52-Week Range
$1.51 – $59.70
Volume
$4.69B
Avg Volume
$5.95B
Shares Outstanding
1.5M
Next Earnings
Nov 11, 2026

Fundamentals Snapshot

Annual Revenue
$630,967
Last Q Revenue
$150,098
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-35.63
Dividend Yield
0.00%
Dilution (1yr)
+757.3%

Why Investors Own APUS

  • ✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 37% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

APUS logo

APIMEDS PHARMACEUTICALS US I

APUS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$12M▲ +834.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +1124.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.1M▲ +757.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$6M▼ −$6M YoY
StockOtter · stockotter.space

About APIMEDS PHARMACEUTICALS US I

Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$4.99
▲ +2.8% Upside
High Target$6.25
Low Target$4.38
Based on 10 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

APIMEDS PHARMACEUTICALS US I tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift APUS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

APIMEDS PHARMACEUTICALS US I announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.